(Eds: Disclaimer: The following press release comes to you under an arrangement with Business Wire India. PTI takes no editorial responsibility for the same.)Coimbatore, Tamil Nadu, India Business Wire India
Rheumatological conditions/autoimmune diseases have been increasing at an alarming rate, early detection can help arrest disease progression and prevent complications. The Department of Rheumatology & Clinical Immunology at Sri Ramakrishna Hospital provides an in-depth look into various rheumatological conditions and the signs to look for to make an early diagnosis.
Rheumatology is a subspeciality of medicine, which involves the study of muscles, tendons and joints. Immunology deals with the immune system, which is the first line of our bodys natural defence system. It plays a vital role in safeguarding us from various illnesses affecting our bodies. However, when this immune system fails to function properly, it leads to many autoimmune diseases.
Rheumatic diseases can affect any part of the body, from head to toes. It may start as simple as a fever or rash, and these signs may only be the beginning of a serious underlying health problem. Rheumatological conditions need to be diagnosed and treated at the earliest to avoid long-term complications, including joint deformities and disabilities. General awareness of rheumatology and immunology is necessary to make an early diagnosis and avoid unwanted long-term sequelae.
Rheumatoid arthritis
The most common form of immune-mediated inflammatory arthritis is Rheumatoid Arthritis (RA). It generally affects the joints either on one side or both sides of the body. This condition usually starts as joint pain, swelling and stiffness, and if left ignored, it could progress to deformities and severe restriction in motion. In addition, RA can affect other parts of the body including the skin, eyes, lungs, heart, and kidneys.
Ankylosing spondylitis
Ankylosing spondylitis (AS) is another form of immune-mediated inflammatory arthritis and is a type of seronegative arthritis. AS typically affects adolescents and young adults, causing back pain and stiffness, more pronounced first thing in the morning and after prolonged rest. It causes spine deformity and a stopped posture if left untreated. AS also affects peripheral joints and cause extra-articular features, commonly affecting eyes (uveitis), skin (psoriasis) and bowel (inflammatory bowel disease).
Psoriatic arthritis and other Seronegative arthritis
Psoriatic Arthritis (PsA) is another type of seronegative arthritis which occurs in one-third of patients with skin or scalp psoriasis. It can occur even before or concurrently, or after developing psoriasis. There are also other types of seronegative arthritis such as Reactive Arthritis, Spondyloarthropathy (SpA) and Enteropathic Arthritis (arthritis due to ulcerative colitis and Crohns disease). These conditions are collectively labelled as seronegative arthritis as the blood test for rheumatoid factor (RF) is negative. They share many clinical, radiological and genetic features, different from RA.
Various traditional and contemporary treatments are available for RA, AS, PsA and other seronegative arthritis. Conventional treatments are called disease-modifying anti-rheumatic drugs (DMARDs), and modern treatments are constantly evolving to target specific proteins (Cytokines), which perpetuate the disease process. These modern drugs are called Targeted Therapies and Biologics, which have revolutionized the treatment of arthritis. These contemporary treatments are in the form of tablets, injections, and infusions.
Gout and Pseudogout
Gout is the most common form of Inflammatory Monoarthritis (arthritis affecting a single joint), and the great toe is the most common joint affected. It causes sudden onset of excruciating joint pain associated with swelling, redness and heat. It is due to a buildup of high uric acid levels in the body with the deposition of uric acid crystals in the affected joint. It is generally due to the high intake of a purine-rich / high protein diet. Alcohol is another common risk factor for gout, and lifestyle modifications including reducing weight, increasing physical activities, adequate hydration and avoiding a high purine diet and alcohol are crucial in the treatment and prevention of gout. Pseudogout is another form of crystal arthritis that mimics gout, and it is usually secondary to certain medical conditions and not due to dietary risk factors.
Connective tissue diseases and Vasculitis
Connective Tissue Diseases (CTD) and vasculitis are also common rheumatological conditions, and the examples include Lupus (SLE), Sjogrens syndrome, Scleroderma, Mixed Connective Tissue Disorder (MCTD) and Myositis. They can cause many symptoms affecting various organs with or without Arthritis, so patients with these conditions may present to different specialists with diverse symptoms. It is crucial to diagnose these conditions very early and treat them aggressively to prevent major organ or life-threatening complications. Modern treatments including biologics are now available to effectively manage these once dreadful conditions.
Osteoporosis
As the name implies, this condition leads the bones to become porous and weakens the bone to a great extent, resulting in a fracture. Osteoporosis is aptly called a silent disease as the condition may go unnoticed for a long time, and the first presentation may be a fracture without any trauma. It is most common in post-menopausal women, but it can affect young women and men due to some risk factors. It can be effectively treated using both conventional and modern drugs in the form of tablets, subcutaneous injections and intravenous infusions.
Juvenile Idiopathic Arthritis (JIA) and other childhood rheumatological conditions
JIA is similar to the adult form of immune-mediated inflammatory arthritis such as RA, AS and PsA that occurs in children aged 16 or younger. Treatment for JIA are similar to the adult form of arthritis, and they include DMARDs, targeted therapies and biologics. A child needs to be diagnosed at the earliest and treated intensively to prevent irreversible joint damage and other unwanted long-term sequelae. Periodic Fever Syndromes (PFS) or Systemic Autoinflammatory Disorders (SAID) are other rare forms of childhood rheumatological conditions that commonly present with fever and rash with or without arthritis. These conditions require careful evaluation and management by experts with modern treatments to stop disease progression and prevent complications.
About The Department of Rheumatology & Clinical Immunology
The Rheumatology & Clinical Immunology Department at Sri Ramakrishna Hospital has an experienced rheumatology team. In addition, it has close links with other medical and surgical specialities, including allied therapies such as physiotherapy and orthotics, to provide an efficient multidisciplinary service.
It has full-fledged laboratory facilities, including immunology, biochemistry, microbiology, haematology, and histopathology, which assist in making a precise diagnosis and starting appropriate treatment as early as possible.
Sri Ramakrishna Hospital (https://www.sriramakrishnahospital.com) also has an excellent radiology & nuclear medicine department with state-of-the-art imaging facilities, including musculoskeletal ultrasound (US), MRI, CT, HRCT, x-rays, bone mineral density (BMD/DEXA), whole body, as well as three-phase isotope bone scan and PET-CT.
About Sri Ramakrishna Hospital
Sri Ramakrishna Hospital has attained an iconic reputation since its inception in 1975. Situated right in the heart of Coimbatore city, this hospital has in many ways become a part of medical history. In fact, it has been an integral part of the healthcare revolution of modern India. Established and run by the SNR Sons Charitable Trust, Sri Ramakrishna Hospital treats thousands upon thousands of patients each year. From the most advanced procedures to treatments for everyday ailments, they bring relief to patients from all walks of life using state-of-the-art technology and cutting-edge surgical and medical techniques to deliver outstanding outcomes.
PWRPWR
See the original post here:
Rheumatology and the Things One Needs to Care About - THE WEEK
- Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment ... - Dermatology Times - April 18th, 2024 [April 18th, 2024]
- Psoriasis Patients with Arthralgia At Increased Risk of Psoriatic Arthritis Development - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Diagnosing Psoriatic Arthritis for the Dermatologist: Guidance From the Experts - Medscape - April 18th, 2024 [April 18th, 2024]
- Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg - MD Magazine - April 18th, 2024 [April 18th, 2024]
- The Impact of Pediatric Plaque Psoriasis on Children and Caregivers - HMP Global Learning Network - April 18th, 2024 [April 18th, 2024]
- Guselkumab Led to Improvements Over Several Psoriatic Arthritis Disease Domains - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Dual Diagnosing and Managing Psoriasis and Psoriatic Arthritis - The Dermatologist - April 18th, 2024 [April 18th, 2024]
- Etanercept Effective for Psoriasis, Rheumatic Disease Among Patients Extending Treatment After 12-Weeks - MD Magazine - February 9th, 2024 [February 9th, 2024]
- High Response Rates in Psoriasis With Oral IL-23 Inhibitor - Medpage Today - February 9th, 2024 [February 9th, 2024]
- Psoriasis and eczema have complex causes and consequences that researchers are seeking to uncover - Medical Xpress - February 9th, 2024 [February 9th, 2024]
- New Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- No Difference in Psoriasis Immune Response Despite Switch Between AVT02, Adalimumab - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Breakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from Phase II Trial of Oral Interleukin Inhibitor for Psoriasis Treatment - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva - February 9th, 2024 [February 9th, 2024]
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 9th, 2024 [February 9th, 2024]
- Rising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva - February 9th, 2024 [February 9th, 2024]
- Global Psoriatic Arthritis (PsA) Treatment Market to achieve a remarkable US$ 15.6 Billion by 2028, - PharmiWeb.com - February 9th, 2024 [February 9th, 2024]
- Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter - May 31st, 2023 [May 31st, 2023]
- Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com - May 31st, 2023 [May 31st, 2023]
- Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena - May 31st, 2023 [May 31st, 2023]
- No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena - May 30th, 2023 [May 30th, 2023]
- Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- The Weekly Roundup: May 22-26 - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Pediatric Psoriasis Market: A Study of the Industry's Key Applications ... - The Navajo Post - May 30th, 2023 [May 30th, 2023]
- Phototherapy Lamps Market are set to witness a CAGR of 5.8 ... - Digital Journal - May 30th, 2023 [May 30th, 2023]
- Celltrion seeks approval for Stelara biosimilar in EU - The Investor - May 30th, 2023 [May 30th, 2023]
- Peter Marinkovich, MD: FDA Approval of B-VEC Gene Therapy for ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Clinical Utility of Deucravacitinib for the Management of Moderate to ... - Dove Medical Press - May 18th, 2023 [May 18th, 2023]
- Covid-19 and Psoriasis: Is there a link? - Dunya News - May 18th, 2023 [May 18th, 2023]
- Improvement Needed in Study Interventions to Better Skin Self ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine - May 18th, 2023 [May 18th, 2023]
- Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- NOVN: Counting Down to PDUFA - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights - May 18th, 2023 [May 18th, 2023]
- New campaign raises awareness of topical steroid withdrawal - Professional Beauty - May 18th, 2023 [May 18th, 2023]
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in... - February 2nd, 2023 [February 2nd, 2023]
- EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -... - February 2nd, 2023 [February 2nd, 2023]
- 12 Ways to Treat Psoriasis at Home - Healthline - January 22nd, 2023 [January 22nd, 2023]
- DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes - January 19th, 2023 [January 19th, 2023]
- Types of Psoriasis: Pictures, Symptoms and Treatments - Healthline - December 18th, 2022 [December 18th, 2022]
- Psoriasis Pathogenesis and Treatment - PMC - PubMed Central (PMC) - November 23rd, 2022 [November 23rd, 2022]
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? - November 23rd, 2022 [November 23rd, 2022]
- Im a Dermatologist and These 7 Things Could Be Making Your Psoriasis Worse - Well+Good - October 19th, 2022 [October 19th, 2022]
- 'Worst time of the year for me to be covered in scabs': Amber Heard's Alleged Ex Cara Delevingne Revealed Her Psoriasis Struggle Made Kate Moss Scream... - October 19th, 2022 [October 19th, 2022]
- Psoriasis: What It Is, Symptoms, Causes, Types & Treatment - October 17th, 2022 [October 17th, 2022]
- What is psoriasis and which foods ease symptoms? - Evening Standard - October 17th, 2022 [October 17th, 2022]
- Chronic inflammatory diseases: what they are - Emergency Live International - October 17th, 2022 [October 17th, 2022]
- How remote care can deliver a step change in treatment for inflammatory skin conditions - PoliticsHome - October 17th, 2022 [October 17th, 2022]
- Probiotics Supplementation may Improve Symptoms of Hyperuricemia and Gout - Rheumatology Network - October 15th, 2022 [October 15th, 2022]
- Psoriasis Pathogenesis and Treatment - PubMed - October 2nd, 2022 [October 2nd, 2022]
- Best and Worst Drinks for Psoriasis - Everyday Health - October 2nd, 2022 [October 2nd, 2022]
- These Are the 10 Most Common Chronic Skin Conditionsand the Most Important Facts to Know About Them - Parade Magazine - October 2nd, 2022 [October 2nd, 2022]
- Survey Addresses Concerns Regarding Reproductive Healthcare Communication in Women with RA, PsA - Rheumatology Network - October 2nd, 2022 [October 2nd, 2022]
- Psoriasis Types, Symptoms & Causes | NIAMS - September 29th, 2022 [September 29th, 2022]
- What Is Psoriasis And Can It Be Treated? - Forbes - September 29th, 2022 [September 29th, 2022]
- Plaque Psoriasis Treated With Tildrakizumab Shown to be Effective in Real-World Settings - MD Magazine - September 29th, 2022 [September 29th, 2022]
- Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis - Business Wire - September 29th, 2022 [September 29th, 2022]
- 15 Items That Will Make Your Life With Psoriatic Arthritis Easier - BlackDoctor.Org - September 29th, 2022 [September 29th, 2022]
- Types of Psoriasis and Their Effects on the Immune System - Cureus - September 27th, 2022 [September 27th, 2022]
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis - BioSpace - September 27th, 2022 [September 27th, 2022]
- How diversity and inclusion continues to be incorporated in dermatology - PMLiVE - September 27th, 2022 [September 27th, 2022]
- Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp A - Benzinga - September 27th, 2022 [September 27th, 2022]
- Psoriasis Treatment Market Size to Hit USD 51.24 Bn by 2030 - GlobeNewswire - August 15th, 2022 [August 15th, 2022]
- Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage - Benzinga - August 15th, 2022 [August 15th, 2022]